Yet another high profile pharmaceutical plagued by side effects:
March 30, 2007 (East Hanover, NJ) - Novartis, in compliance with an FDA request, has suspended marketing and sales of its irritable bowel/constipation drug Zelnorm (tegaserod maleate), after an analysis of its clinical database pointed to a higher incidence of MI, stroke, and unstable angina among patients taking the drug.
You have to sign up (free) to view the article. I didn't realize that at the time of posting. The gist of the article is in the first paragraph, posted above.